Telmisartan (80mg) + Amlodipine (5mg) + Hydrochlorothiazide (12.5mg) (Medical Monograph)

Overview

A triple-drug, fixed-dose combination (FDC) antihypertensive therapy containing an angiotensin II receptor blocker (ARB), a dihydropyridine calcium channel blocker (CCB), and a thiazide diuretic. It is indicated for the treatment of essential hypertension in patients whose blood pressure is not adequately controlled on any two of the following drug classes: ARBs, CCBs, and thiazide diuretics. This combination provides synergistic action, improved compliance, and is a cost-effective strategy for hypertension management in the Indian population.

This combination exerts a multi-faceted antihypertensive effect: 1) Telmisartan selectively and competitively blocks the binding of angiotensin II to the AT1 receptor, inhibiting vasoconstriction and aldosterone secretion. 2) Amlodipine inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, causing peripheral arterial vasodilation. 3) Hydrochlorothiazide inhibits sodium reabsorption in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, reducing plasma volume.